How We Build Our Partner Network

AxioTechBio builds its partner network strategically, technology by technology, to provide clients with comprehensive access to the modern genomics, multi-omics, and precision medicine ecosystem across both research and clinical diagnostics.
Rather than creating overlapping capabilities within the same specialty, we carefully select complementary partners whose expertise allows us to cover the full value chain, from biomarker discovery and translational research to clinical implementation and routine diagnostics.
Our network encompasses a broad range of technologies and scientific disciplines, including:
  • Next-generation sequencing (NGS), including whole genome sequencing (WGS), whole exome sequencing (WES), targeted panels, long-read sequencing, and emerging sequencing technologies.
  • Single-cell, spatial and cellular-resolution omics, including single-cell genomics, transcriptomics, epigenomics and spatial biology platforms.
  • Transcriptomics and RNA profiling, including bulk RNA-seq, single-cell RNA-seq, gene expression analysis, transcriptome characterization, liquid biopsy applications, circulating tumor DNA (ctDNA), cfDNA and cfRNA.
  • Epigenomics and epigenetic profiling, including DNA methylation analysis, chromatin accessibility, ATAC-seq, histone modification studies and epigenetic biomarker development.
  • Proteomics, including discovery, quantitative and targeted proteomics, biomarker identification, mass spectrometry-based protein analysis and translational proteomics.
  • Metabolomics and lipidomics, including untargeted and targeted metabolite profiling, biomarker discovery, metabolic pathway analysis and systems biology approaches.
  • Multi-omics integration, combining genomic, transcriptomic, proteomic and metabolomic datasets to support precision medicine, stratified healthcare and advanced research projects.
  • Cytogenetics and molecular cytogenetics, including karyotyping, FISH, chromosomal microarrays (CMA) and structural variant analysis.
  • Clinical and diagnostic genetic testing, covering germline and somatic testing for rare diseases, hereditary disorders, oncology, reproductive genetics and inherited conditions.
  • Precision oncology and companion diagnostics, including molecular profiling, predictive biomarkers and therapy selection support.
  • Pharmacogenomics and personalized medicine, enabling optimization of therapeutic strategies based on individual genetic and molecular profiles.
  • Microbiome and metagenomics analysis, supporting research and clinical applications involving microbial communities and host-microbiome interactions.
  • Bioinformatics and computational biology, including genomic data interpretation, clinical reporting, AI-assisted analytics, software platforms and decision-support solutions.

How We Work With Partners

We tailor our engagement to the stage and goals of each partnership — from support on a single defined opportunity to sustained market development.

Tender & Opportunity Representation
For companies with a specific commercial opportunity — a public tender or procurement process — we manage:

  • Opportunity qualification and strategy

  • Technical and commercial positioning

  • Proposal coordination

  • Commercial representation through to contract award

Ongoing Market Development
For companies seeking a sustained presence in the region, we take on proactive, longer-term business development:

  • Lead generation and prospecting

  • Continuous tender monitoring

  • Key account management

  • Relationship-building with research centers, hospitals and healthcare organizations

Every engagement is structured individually around the partner's goals — get in touch and we'll define the right model together.